Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06071702
Other study ID # IoNIR-002
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2024
Est. completion date August 2029

Study information

Verified date October 2023
Source Medinol Ltd.
Contact Brenda Koltun Reuven
Phone +972542666688
Email brendak@medinol.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multi-center, single-arm, open-label, early feasibility study to provide preliminary evidence for the safety and efficacy of the novel IoNIR stent system


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date August 2029
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years. 2. Patient with an indication for PCI including NSTEMI (biomarkers have peaked or are falling), angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of =70%, a positive non-invasive stress test, or FFR =0.80, Pd/Pa=0.91or iFR, RFR, DFR, DPR=0.89 must be present). 3. Non-target vessel PCIs are allowed if performed >30 days prior to index procedure. 4. Patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule. 5. Staged procedures are allowed as long as the IoNIR stent is implanted in the last procedure and at least 30 days have elapsed between the previous procedure and the IoNIR PCI. 6. A maximum of two vessels and up to two lesions may be treated (two lesions separated by up to 10mm that can be covered by a single stent are considered as one lesion). 7. Lesions requiring scoring/cutting and/or rotational/orbital atherectomy and/or intra-vascular lithotripsy are allowed. 8. Overlapping stents are allowed. 9. Target lesion must be in a major native coronary artery with visually estimated diameter of =2.5 mm to =4.0 mm and lesion length of up to 40 mm, and appropriate size IoNIR stents are available. Exclusion Criteria: - 1. ST Segment Elevation MI within past 30 days. 2. NSTEMI with biomarkers that have not peaked. 3. Significant valvular disease or planned valvular intervention. 4. PCI within the 30 days preceding the baseline procedure. 5. PCI in the target vessel within 12 months of the baseline procedure. 6. Planned staged procedures (coronary or valvular), where the study stent is implanted in the first stage. 7. Brachytherapy in conjunction with the baseline procedure. 8. Known history of stent thrombosis. 9. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure <90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including IABP. 10. Subject is intubated. 11. Known LVEF <30%. 12. Contraindication to DAPT for 6 months in non-ACS patients and 12 months in ACS patients (including planned surgeries that cannot be delayed). 13. Subject has an indication such as atrial fibrillation for oral anticoagulation/prolonged heparinization (i.e., use of coumadin/DOAC (NOAC) or prolonged enoxaparin/heparin therapy is not allowed). 14. eGFR <60 mL/min. 15. Hemoglobin <10 g/dL. 16. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3. 17. White blood cell (WBC) count <3,000 cells/mm3. 18. Clinically significant liver disease. 19. Active peptic ulcer or active bleeding from any site. 20. Bleeding from any site within the previous 8 weeks requiring active medical or surgical attention. 21. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath. 22. History of bleeding diathesis or coagulopathy and patients that refuse blood transfusions. 23. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any permanent neurologic defect attributed to CVA. 24. Known allergy to the study stent components (cobalt, nickel, chromium, molybdenum, platinum, PDLG, PLC, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus, everolimus, or similar drugs or any other analogue or derivative or similar compounds). 25. Known allergy to protocol-required concomitant medications such as aspirin, or P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), heparin and bivalirudin, or iodinated contrast allergy that cannot be adequately pre-medicated. 26. Any co-morbid condition that may cause non-compliance with the protocol (e.g., dementia, substance abuse, etc.) or reduced life expectancy to <24 months (e.g., cancer, severe heart failure, severe lung disease). 27. Patient is participating in or plans to participate in any other investigational drug or device clinical trial that has not reached its primary endpoint. 28. Women who are pregnant or breastfeeding. 29. Women who intend to become pregnant within 12 months after the baseline procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the baseline procedure). 30. Patient has received an organ transplant or is on a waiting list for an organ transplant. 31. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the baseline procedure. 32. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are allowed. 33. Complex lesions including severely calcified lesions, presence of visible thrombus, chronic total occlusions, bifurcation lesions (side branch diameter =2.0 mm), tortuous lesions, restenotic lesions, left main lesions, ectasia, aneurysm and any bypass graft lesions. 34. Another lesion in a target or non-target vessel (including all side branches) is present that requires or has a high probability of requiring PCI within 12 months after the baseline procedure. 35. Ostial lesions within 3 mm of origin of LAD, LCx, lesions in the LM.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
IoNIR Ridaforolimus-Eluting Coronary Stent System
The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medinol Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary In-stent Late Loss (LL) In-stent Late Loss (LL) at 13 months assessed by quantitative coronary angiography (QCA) (Minimal Lumen Diameter (MLD) post-procedure - MLD follow-up (US patients only)) 13 months
Primary Target Lesion Failure Target Lesion Failure (composite of cardiovascular death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization) 1 year
Secondary Major adverse cardiac events Major adverse cardiac events (MACE; the composite rate of cardiovascular death, any MI or ischemia-driven target lesion revascularization (TLR)). 30 days, 6 months, 1,2,3,4,5 years
Secondary All-cause mortality All-cause mortality 30 days, 6 months, 1,2,3,4,5 years
Secondary Cardiovascular death Cardiovascular death 30 days, 6 months, 1,2,3,4,5 years
Secondary Myocardial infarction Myocardial infarction 30 days, 6 months, 1,2,3,4,5 years
Secondary Target vessel related MI Target vessel related MI 30 days, 6 months, 1,2,3,4,5 years
Secondary Target Lesion Failure Target Lesion Failure 6 months, 2, 3, 4, 5 years
Secondary Ischemia-driven TLR Ischemia-driven TLR 30 days, 6 months, 1, 2, 3, 4, 5 years
Secondary Ischemia-driven Target Vessel Revascularization Ischemia-driven Target Vessel Revascularization 30 days, 6 months, 1, 2, 3, 4, 5 years
Secondary Stent thrombosis Stent thrombosis (ARC-2 definite and probable). 30 days, 6 months, 1, 2, 3, 4, 5 years
Secondary Acute Device Success Acute Device Success (successful crossing and deployment with residual QCA DS <30%) index procedure
Secondary Luminal gain Luminal gain (MLD post-procedure - MLD pre-procedure) 13 months - US patients only
Secondary In-stent MLD In-stent MLD 13 months - US patients only
Secondary In-segment MLD In-segment (+5mm from the stent edges) MLD 13 months - US patients only
Secondary In-segment late loss In-segment (+5mm from the stent edges) late loss 13 months - US patients only
Secondary Proximal late loss Proximal late loss (+5 mm from proximal stent edge) 13 months - US patients only
Secondary Distal late loss Distal late loss (+5 mm from proximal stent edge) 13 months - US patients only
Secondary In-stent and in-segment Binary Restenosis In-stent and in-segment Binary Restenosis 13 months - US patients only
Secondary OCT-determined inner layer percent neointimal hyperplasia volume OCT-determined inner layer percent neointimal hyperplasia volume 13 months - US patients only
Secondary In-stent MLA In-stent MLA 13 months - US patients only
Secondary In-segment minimum lumen area (MLA) In-segment minimum lumen area (MLA) 13 months - US patients only
Secondary Minimal stent area (MSA) Minimal stent area (MSA) 13 months - US patients only
Secondary Stent expansion Stent expansion 13 months - US patients only
Secondary Edge dissection Edge dissection 13 months - US patients only
Secondary % NIH at the MLA % NIH at the MLA 13 months - US patients only
Secondary % Area stenosis at the MLA % Area stenosis at the MLA 13 months - US patients only
Secondary Luminal gain (MLA post-procedure - MLA pre-procedure) Luminal gain (MLA post-procedure - MLA pre-procedure) 13 months - US patients only
Secondary In-stent late loss MLA In-stent late loss MLA 13 months - US patients only
Secondary In-segment (+5 mm from the stent edges) late loss (MLA). In-segment (+5 mm from the stent edges) late loss (MLA). 13 months - US patients only
Secondary Proximal late loss (+5 mm from proximal stent edge) (MLA) Proximal late loss (+5 mm from proximal stent edge) (MLA) 13 months - US patients only
Secondary Distal late loss (+5 mm from distal stent edge) (MLA) Distal late loss (+5 mm from distal stent edge) (MLA) 13 months - US patients only
Secondary Intraluminal mass at least 0.2 mm beyond the luminal edge of a strut Intraluminal mass at least 0.2 mm beyond the luminal edge of a strut (Intraluminal mass attached to the vessel is defined as an irregularly shaped structure in contact with the luminal contour, a free intraluminal mass is defined as an isolated structure in the lumen without contact to the vessel wall) 13 months - US patients only
Secondary Malapposition Malapposition (stent struts clearly separated from the vessel wall (lumen border/plaque surface) without tissue behind the struts with a distance from the adjacent intima of =0.2 mm not associated with any side branch) 13 months - US patients only
Secondary % Covered strut % Covered strut (NIH thickness of >0 µm). 13 months - US patients only
Secondary % Healthy covered strut % Healthy covered strut (NIH thickness=40 µm). 13 months - US patients only
Secondary Peri-strut low intensity area Peri-strut low intensity area (peri-strut region of homogeneous lower intensity observed without signal attenuation). 13 months - US patients only
Secondary Healing score Healing score (defined as % intraluminal mass [=intraluminal mass volume/stent volume] ×4 + % malposed and uncovered struts
×3 + (% uncovered struts alone ×2 + % malposed struts alone ×1) at 13 months.
Intraluminal mass (+4).
Malposed and uncovered struts (+3).
Uncovered struts alone (+2).
Malposed struts alone (+1).
13 months - US patients only
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A